Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

Time frame: The time from the date of enrollment to the date of death from any cause, assessed up to three years after randomizationof the last patient

Population: When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC.~Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.

Patients should not receive additional TACE therapy in this study after meeting any of the following conditions, at the Investigator's discretion. 1. The patient develops an intra-hepatic lesion that is uncontrolled by serial TACE 2. Deterioration in arterial pathways to treat HCC that makes additional TACE impossible 3. Severe vascular invasion occurs that makes additional TACE impossible 4. Extra hepatic spread considered relevant to life expectancy that requires another treatment modality for HCC 5. Liver function at grade Child-Pugh class C lasting for 28 days

Time frame: The time from the date of enrollment to the date of event for TACE discontinuation, assessed up to three years after randomizationof the last patient

Population: When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC.~Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.